Trial Profile
An Open-Label Phase II Study of Lirilumab (BMS-986015) in Combination With 5-Azacytidine (Vidaza) for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 25 Sep 2019
Price :
$35
*
At a glance
- Drugs Lirilumab (Primary) ; Azacitidine; Azacitidine
- Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 05 Sep 2019 Status changed from completed to discontinued.
- 27 Jul 2018 Status changed from active, no longer recruiting to completed.
- 12 Dec 2017 Results (n=35) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology